Technical Analysis for XCUR - Exicure Inc

Grade Last Price % Change Price Change
grade C 2.7 18.94% 0.4300
XCUR closed up 18.94 percent on Friday, September 27, 2019, on 3.7 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical XCUR trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Volume Surge Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 18.94%
Shooting Star Candlestick Bearish 18.94%
Lizard Bearish Bearish Day Trade Setup 18.94%

Older signals for XCUR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Exicure, Inc., a clinical stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. The company's three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an antisense SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA containing tumor necrosis factor antisense oligonucleotides. It is also developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis; and marketing dupilumab, a human monoclonal antibody for treating moderate to severe atopic dermatitis in the United States. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Biotechnology Medical Specialties RTT Branches Of Biology Biology Alpha Monoclonal Antibodies Psoriasis Atopic Dermatitis Dermatitis Stage Biotechnology Sense Tumor Necrosis

Is XCUR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 6.5
52 Week Low 1.62
Average Volume 29,087
200-Day Moving Average 2.9801
50-Day Moving Average 2.6243
20-Day Moving Average 2.3852
10-Day Moving Average 2.2105
Average True Range 0.2290
ADX 25.21
+DI 29.8555
-DI 22.8636
Chandelier Exit (Long, 3 ATRs ) 2.0730
Chandelier Exit (Short, 3 ATRs ) 2.3070
Upper Bollinger Band 2.8794
Lower Bollinger Band 1.8910
Percent B (%b) 0.82
BandWidth 41.4389
MACD Line -0.1094
MACD Signal Line -0.1360
MACD Histogram 0.0266
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.9100
Resistance 3 (R3) 2.9067 2.8333 2.8750
Resistance 2 (R2) 2.8333 2.7799 2.8350 2.8633
Resistance 1 (R1) 2.7667 2.7468 2.7300 2.7700 2.8517
Pivot Point 2.6933 2.6933 2.6750 2.6950 2.6933
Support 1 (S1) 2.6267 2.6399 2.5900 2.6300 2.5483
Support 2 (S2) 2.5533 2.6068 2.5550 2.5367
Support 3 (S3) 2.4867 2.5533 2.5250
Support 4 (S4) 2.4900